Amgen (Belgium)

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP

André Bosly, Dominique Bron, Ambro van Hoof et al. · Annals of Hematology · 2007 · 173 citations

Medicine, Hematology, Oncology +9

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

Joseph A. Markenson, Allan Gibofsky, William Palmer et al. · The Journal of Rheumatology · 2011 · 95 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma

Kelly Fust, Xiaoyan Li, Michael Maschio et al. · PharmacoEconomics · 2016 · 34 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +13

Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC

Nele Boeckx, Andrew Toler, Ken Op de Beeck et al. · Annals of Oncology · 2016 · 22 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers

George Kafatos, Sabada Dube, Peter Burdon et al. · Clinical Colorectal Cancer · 2020 · 17 citations

Pharmacy, Dermatology, Oncology +17